Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €22.75 EUR
Change Today +0.17 / 0.75%
Volume 87.9K
As of 11:35 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

ion beam applications (IBAB) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/10/15 - €25.48
52 Week Low
04/28/14 - €9.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ION BEAM APPLICATIONS (IBAB)

Related News

No related news articles were found.

ion beam applications (IBAB) Related Businessweek News

No Related Businessweek News Found

ion beam applications (IBAB) Details

Ion Beam Applications SA operates as a cancer diagnostics and treatment equipment company in Belgium, the United States, and internationally. The company develops, manufactures, and supports medical devices and software solutions for cancer treatment by proton beam therapy. It operates in two segments, Proton therapy and Particle accelerators, and Dosimetry. The Proton therapy and Particle accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of Positron Emission Tomography or Single Photon Emission Computed Tomography radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment offers measurement and quality assurance instruments for radiotherapy and medical imaging to enable the healthcare professionals to verify that equipment administers the planned dose to the targeted area. The company was founded in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

1,100 Employees
Last Reported Date: 03/26/15
Founded in 1986

ion beam applications (IBAB) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: €615.0K
Compensation as of Fiscal Year 2013.

ion beam applications (IBAB) Key Developments

IBA and Toshiba Sign Strategic Partnership in Particle Therapy

IBA (Ion Beam Applications S.A.) and Toshiba Corporation announced the signing of a global collaboration to expand access to advanced particle therapy worldwide. Toshiba Medical Systems Corporation will become the distributor in Japan for Proteus®ONE, IBA’s compact single-room proton therapy solution, and IBA will become the agent for Toshiba’s Carbon Therapy Solutions outside Japan. IBA and Toshiba will collaborate on activities such as customer education for Proteus®ONE and Toshiba's carbon therapy solutions. The collaboration will also enable both organizations to mutually leverage their Operation and Maintenance (O&M) services.

Ion Beam Applications S.A. Launches myQA, New Global Quality Assurance Platform

Ion Beam Applications S.A. (IBA) has launched the new global quality assurance platform, myQA. myQA offers full support throughout all QA applications and provides the user access to their various software modules and data from one intuitive platform - anytime and anywhere. The myQA Platform offers an all-in-one interface that completely redesigns how the user is able to manage and organize their QA applications. It enhances the QA workflow and maximizes efficiency by integrating all QA software modules into one platform and one Central Database (SQL) - which is accessible throughout the department and even satellites. Using the myQA Cockpit, users can maintain connectivity by reviewing and tracking their patient data and machine QA status from anywhere and on various devices, including smartphones and tablets. It also allows the user to keep an instant overview with simple and clear reporting on one screen. With the myQA Cloud, the user is given a unique outlet to perform benchmarking of their QA data for best practice checks and full trust in their results. The myQA Cloud grants users the opportunity to anonymously connect with peers and data from around the world.

Ion Beam Applications, S.A. Reports Consolidated Annual Results for the Year of 2014

Ion Beam Applications, S.A. reported consolidated annual results for the year of 2014. For the year, the company reported total net sales of EUR 220,577,000 against EUR 212,512,000 a year ago. Profit Before Tax was EUR 17,173,000 against loss before tax of EUR 408,000 a year ago. Net result was EUR 24,294,000 against negative net result of EUR 1,011,000 a year ago. Total revenue impacted by low backlog conversion rate of Dosimetry.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBAB:BB €22.75 EUR +0.17

IBAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Analogic Corp $86.90 USD -1.16
Balchem Corp $54.76 USD -0.115
Mallinckrodt PLC $117.58 USD -4.43
Sumitomo Heavy Industries Ltd ¥808.00 JPY +3.00
Varian Medical Systems Inc $94.88 USD -0.62
View Industry Companies

Industry Analysis


Industry Average

Valuation IBAB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 23.9x
TEV/Sales 2.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ION BEAM APPLICATIONS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at